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PESTE DES PETITS RUMINANTS (PPR) THERMOTOLERANT VACCINE 
PRODUCTION AND DELIVERY THROUGH A PUBLIC-PRIVATE 




The public-private partnership between 
Mali Laboratoire Central Vétérinaire 
(LCV), ILRI and Hester Biosciences Ltd 
of India led to the production of two 
thermotolerant vaccines for Peste des 
Petits Ruminants (PPR).  
Malian livestock farmers are willing to pay 
for the vaccines because they will prevent 
infection and greatly reduce the risk of 
loss of livestock. 
Business models to scale up the vaccines 
in Mali and beyond its borders are needed 
to vaccinate more livestock. Veterinarians 
support greater availability of the 
vaccine to increase coverage of livestock, 
especially in remote areas.  
Each year, PPR causes economic losses 
worth an estimated USD 1.2 to 1.7 billion, 
due to animal deaths, reduced production 
and the cost of fighting the disease. 
Investing in the control and eradication 
of PPR will significantly contribute to 
food security and reducing poverty in the 
world’s most vulnerable pastoral and rural 
communities.
SUMMARY 
Peste des Petits Ruminants (PPR) is caused by a highly contagious, acute virus 
(similar to rinderpest) that primarily affects domestic small ruminants (SRs) like 
sheep and goats. It is a widespread, virulent, and devastating disease, with huge 
economic, food security and livelihood impacts, especially for livestock owners 
who keep SRs. The animal health and development communities are concerned 
because the disease is spreading across eco-regions and affecting the livelihoods 
and nutrition status of hundreds of millions of people. 
Given the lack of data on PPR, most endemic countries are unaware of the 
magnitude of the impact of the disease on their economies. Each year, PPR causes 
economic losses worth an estimated USD 1.2 to 1.7 billion, due to animal deaths, 
reduced production and the cost of fighting the disease. Approximately a third of 
the financial impact occurs in Africa and a quarter in South Asia (OIE and FAO 2015). 
Investing in the control and eradication of PPR will significantly contribute to food 
security and reducing poverty in the world’s most vulnerable pastoral and rural 
communities such as women who often hold SRs.  
Promisingly, global consensus has been reached on the need to control and 
eradicate PPR. A Control and Eradication Strategy was endorsed at the International 
Conference for the Control and Eradication of PPR, organized by the Food and 
Agriculture Organization of the United Nations (FAO) and the World Organisation 
for Animal Health (OIE) in 2015. Eradication of the disease by 2030 is its goal (OIE 
and FAO 2015). 
















A woman milks a goat in Ségou District, Mali. Sheep and goats 
are an important source of nutrition and livelihoods for millions 
of people in the Sahel.
VACCINATING AGAINST PPR: CHALLENGES AND OPPORTUNITIES
The principal method for the control of PPR is vaccination. It 
is important that all SRs are vaccinated because introduction 
of unvaccinated animals into a herd is likely to result in the 
introduction of the virus. There is a homologous live attenuated 
vaccine that protects SRs against PPR to control losses. The 
vaccine has shown to be effective for at least three years post-
vaccination (equivalent to the average lifespan of a SR). It is 
produced by private and public laboratories who commercialize 
it, although laboratories only exist in a few countries, making 
access difficult for non-producing countries.  
This type of vaccine also requires cold storage, and the lack of 
proper cold chain infrastructure is a major cause of failure in 
most vaccination programs, especially in countries with very 
high temperatures.  It is often impossible to keep vaccines cold 
when travelling long distances in rural areas, and lack or failures 
of electricity, even in urban areas, means use of the current 
vaccine is constrained.  
Sufficient thermostability of the current vaccines for use without 
a cold chain will greatly facilitate the delivery of vaccination. 
This will remove the need for heavy cold chain maintenance and 
will have a significant impact on reducing costs of PPR control 
programs. It is also expected that vaccination campaigns will be 
more effective in terms of immunity gains against PPR because 
failure due to breakdown in cold-chain maintenance would be 
reduced.  
Since 2016, the International Livestock Research Institute (ILRI) 
has partnered with Hester Biosciences Ltd of India (HBS), a 
private vaccine production company, to support the Central 
Veterinary Laboratory (LCV) of Mali in optimizing and producing 
two thermotolerant PPR vaccines:  
1. “ILRI thermotolerant PPR vaccine produced by the Thermovac 
process” (Mariner et al. 2017) developed by ILRI and referred 
here as “ILRI protocol”.
2. Xerovac an old vaccine whose technology existed already at 
LCV (Worrall et al. 2000) but has never been marketed by the 
government because Malian farmers don’t like its texture 
which they perceive as a sign of deterioration. 
The proposed vaccines have proved considerably stable at 
ambient temperatures up to seven days for the ILRI protocol 
and fourteen days at 40°C for the Xerovac protocol, which has 
tremendous advantage in hot countries and in remote areas. The 
project has gone beyond technology development to identify 
and test components of new institutional model for delivering 
effective PPR control services to SRs producers in Mali. 
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A vaccinator in a herd of sheep in Sikasso, Mali.
A teenage girl and one of her family’s sheep at an urban farm in Bamako, 
Mali.


































The two vaccines (ILRI protocol and Xerovac) targeted for 
thermostability are made of the live attenuated Nigeria 
75/1 vaccine strain, and their processes mainly differ in the 
inputs used and lyophilization (freeze-drying) techniques. 
A lactalbumin hydrolysate and sucrose stabilizer were used 
in the case of the ILRI protocol; while a stabilizer based on 
trehalose was used for the Xerovac.  
ILRI and LCV researchers tested the vaccines in 2018 and 
2019 for thermostability which was measured at different 
temperatures and time, and the shelf-life of the vaccines was 
determined as the time a vial retained the minimum dose 
required titer as 102,50 DITC50 at the specified temperature. 
The vaccines have passed the Pan African Veterinary Vaccine 
Centre of the African union (AU-PANVAC) external quality 
control.  
Both vaccines meet FAO and OIE thermostability recommended 
standards (which is at least 25°C for 10 days or 40°C for 2 days) 
which is an advantage for hot climate countries in remote 
areas. Some of the advantages of thermotolerance include 
less cold chain maintenance costs leading to less financial 
cost of PPR control programs, thus improved effectiveness 
of vaccination campaigns in terms of immunity gains against 
PPR. Vaccines were then deployed for field validation in the 
Sikasso region of Mali. Results from field testing of Xerovac 
showed 99% effectiveness in protecting the small ruminants. 
Field tests for the ILRI vaccine will be completed in 2022. 
Prior to deployment of vaccines to the field, ex-ante 
assessment studies were carried out to collect feedback from 
stakeholders, such as farmers and veterinarians who are the 
main vaccinators, on how to improve vaccination coverage of 
small ruminants.  
Willingness to vaccinate livestock and to pay for it 
A study on farmers willingness to vaccinate and pay for it 
was carried out with 304 livestock producers in Mopti and 
Sikasso regions. Both distance effects and vaccine quality-
tracker effects were associated with farmer willingness to 
pay more than the current vaccine prices. Farmers practicing 
semi-intensive production systems were willing to pay 20 
percent more than the current vaccine prices, as were users 
who believe in the beneficial effects of vaccination, consider 
the prices of vaccines as fair, and those who believe that 
some vaccines are more important than others. Targeted 
information dissemination campaigns by the Malian authorities 
are needed to address the factors that discourage farmers 
from vaccinating.  Greater price transparency throughout 
the vaccine production and deployment chain is critical, 
while timely availability of vaccine tested for viability would 
increase the willingness to vaccinate while improving access 
(Wane et al. 2019). 
Perception of vaccinators of the thermostable PPR vaccine 
and recommendations to improve vaccination coverage 
A survey on the perception of PPR thermostable vaccines 
was conducted with 35 veterinarians who provide health 
services to livestock producers in the Sikasso region. Two 
thirds of the vaccinators welcomed the introduction of a new 
thermotolerant vaccine. Others showed concerns that farmers 
might start self-medicating as they can now store the vaccines 
given there are no cold-chain requirements. Most vaccinators 
(86%) believe that the thermotolerance of the vaccines will 
have a great socio-economic advantage and they expect a 
high acceptance rate by end users.  
Recommendations provided by veterinarians to improve 
immunization coverage include raising awareness and 
educating farmers on the benefits of vaccination; ensuring 
vaccines are available in large numbers; reducing the price of 
the vaccine at the farmer’s level and improving programming 
and monitoring of vaccination programs.
Process optimization, vaccine production and field testing
Ex-ante assessment of PPR vaccine delivery
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CONCLUSION
ILRI and HBS usefully built-in house local capacity at 
LCV laboratories in Mali to enable production of the two 
thermotolerant PPR vaccines. The added advantage of these 
vaccines is that they will reduce use of cold chain, hence lowering 
investment and reducing the logistical burden for vaccinators.  If 
used, these vaccines have a huge potential in preventing further 
losses due to PPR outbreaks.  These emerging results from 
initial field tests and the encouraging insights from the ex-ante 
assessments, act as the basis for pursuing next steps.
IMPLICATIONS AND 
RECOMMENDATIONS 
• Business models should be developed to make 
the case for the commercialization of the 
vaccines in Mali and beyond its borders. 
• Governments, partners, veterinarians, and 
livestock farmers need to develop a sustainable 
vaccination strategy that looks at consolidating 
the successful stakeholder platform model and 
make a call for investments in the control of PPR 
and other livestock diseases through public-
private-partnership.
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